Adalimumab is a biologic medication used to treat moderate to severe plaque psoriasis in eligible patients. It works by blocking tumor necrosis factor alpha, a protein involved in inflammation. Understanding its treatment process, potential benefits, side effects, and safety precautions can help patients discuss appropriate treatment options with healthcare professionals and make informed decisions about managing their skin condition.
Plaque psoriasis is a chronic immune mediated skin condition that causes raised, red or discolored patches covered with silvery scales. These patches commonly appear on the elbows, knees, scalp, and lower back, although other areas may also be affected. Adalimumab is one treatment option for certain adults and children with plaque psoriasis, depending on age, disease severity, and local prescribing guidelines. Treatment decisions are made by healthcare professionals after evaluating symptoms, medical history, and previous therapies.
Adalimumab is a biologic medicine classified as a tumor necrosis factor alpha inhibitor. Tumor necrosis factor alpha, commonly called TNF alpha, is a signaling protein that contributes to inflammation. In plaque psoriasis, immune system activity promotes inflammation and accelerates the growth of skin cells, leading to the formation of characteristic plaques.
Adalimumab binds to TNF alpha and reduces its activity. This can help decrease inflammation and improve psoriasis symptoms in patients who respond to treatment. It is administered as a subcutaneous injection, meaning the medication is injected beneath the skin.
Treatment eligibility: Healthcare professionals assess disease severity, affected body areas, previous treatments, and overall health before prescribing adalimumab.
Administration: Patients receive instructions on injection techniques, storage, and handling. The prescribed dose and schedule depend on the patient's age, condition, and approved treatment guidance.
Expected response: Improvement may develop over several weeks, although the timing and degree of response vary among individuals.
Treatment monitoring: Follow up appointments help assess skin improvement, treatment tolerance, and whether continued therapy remains appropriate.
Adalimumab does not cure plaque psoriasis, and symptoms may return after treatment is discontinued. Patients should follow their prescribed treatment schedule and consult their healthcare professional before making changes.
Adalimumab may reduce plaque thickness, scaling, redness, and itching in patients who respond to treatment. Improving skin symptoms can also help reduce discomfort and the impact of psoriasis on daily activities. However, its benefits must be considered alongside potential adverse effects and precautions associated with suppressing part of the immune system.
Before starting treatment, healthcare professionals generally review medical history and assess the risk of infections and other complications.
Common side effects: Injection site reactions, headaches, and upper respiratory infections may occur. The severity and frequency of side effects vary.
Serious infections: Adalimumab can increase the risk of serious infections, including tuberculosis. Screening for tuberculosis and assessment for other infections are important before treatment.
Other health considerations: Certain cancers, nervous system disorders, heart failure, and other medical conditions may require special consideration. Patients should disclose their complete medical history.
Vaccination precautions: Live vaccines are generally avoided during treatment. Patients should discuss vaccination plans with their healthcare professional before receiving any vaccine.
When to seek medical advice: Persistent fever, worsening infections, breathing difficulties, or other severe or unusual symptoms require prompt medical evaluation.
Adalimumab should be used under appropriate medical supervision. Patients should report new symptoms, discuss other medicines they take, and attend recommended follow up appointments. A healthcare professional can explain the potential benefits and risks and determine whether adalimumab is an appropriate option based on individual circumstances.